Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.

Grossman R, Tyler B, Rudek MA, Kim E, Zadnik P, Khan U, Blakeley JO, Pathak AP, Brem H.

Cancer Chemother Pharmacol. 2013 Jul;72(1):93-100. doi: 10.1007/s00280-013-2172-3. Epub 2013 May 7.

2.

The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.

Grossman R, Rudek MA, Brastianos H, Zadnik P, Brem H, Tyler B, Blakeley JO.

Cancer Chemother Pharmacol. 2012 Jul;70(1):129-39. doi: 10.1007/s00280-012-1867-1. Epub 2012 May 27.

3.

Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.

Grossman R, Brastianos H, Blakeley JO, Mangraviti A, Lal B, Zadnik P, Hwang L, Wicks RT, Goodwin RC, Brem H, Tyler B.

J Neurooncol. 2014 Jan;116(1):59-65. doi: 10.1007/s11060-013-1268-2. Epub 2013 Nov 2.

4.

Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic.

Wachsberger PR, Lawrence RY, Liu Y, Xia X, Andersen B, Dicker AP.

J Neurooncol. 2011 Nov;105(2):181-90. doi: 10.1007/s11060-011-0580-y. Epub 2011 Apr 23.

PMID:
21516367
5.

Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470.

Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM.

Cancer Res. 2001 Jul 15;61(14):5491-8.

6.
7.

Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment.

Liu HL, Huang CY, Chen JY, Wang HY, Chen PY, Wei KC.

PLoS One. 2014 Dec 9;9(12):e114311. doi: 10.1371/journal.pone.0114311. eCollection 2014.

8.
9.

Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.

Ningaraj NS, Sankpal UT, Khaitan D, Meister EA, Vats TS.

Cancer Biol Ther. 2009 Oct;8(20):1924-33. Epub 2009 Oct 12.

PMID:
19738431
10.

Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.

Marzolini C, Decosterd LA, Shen F, Gander M, Leyvraz S, Bauer J, Buclin T, Biollaz J, Lejeune F.

Cancer Chemother Pharmacol. 1998;42(6):433-40. Erratum in: Cancer Chemother Pharmacol 1999;43(5):439-40.

PMID:
9788568
11.

Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens.

Zhou Q, Guo P, Wang X, Nuthalapati S, Gallo JM.

J Pharmacol Exp Ther. 2007 Apr;321(1):265-75. Epub 2007 Jan 26.

12.

Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.

Carcaboso AM, Elmeliegy MA, Shen J, Juel SJ, Zhang ZM, Calabrese C, Tracey L, Waters CM, Stewart CF.

Cancer Res. 2010 Jun 1;70(11):4499-508. doi: 10.1158/0008-5472.CAN-09-4264. Epub 2010 May 11.

13.

Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.

Zhou Q, Guo P, Gallo JM.

Clin Cancer Res. 2008 Mar 1;14(5):1540-9. doi: 10.1158/1078-0432.CCR-07-4544. Erratum in: Clin Cancer Res. 2008 Aug 15;14(16):5308-9.

14.

Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.

Takahashi O, Komaki R, Smith PD, J├╝rgensmeier JM, Ryan A, Bekele BN, Wistuba II, Jacoby JJ, Korshunova MV, Biernacka A, Erez B, Hosho K, Herbst RS, O'Reilly MS.

Clin Cancer Res. 2012 Mar 15;18(6):1641-54. doi: 10.1158/1078-0432.CCR-11-2324. Epub 2012 Jan 24.

15.

Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model.

Brem S, Tyler B, Li K, Pradilla G, Legnani F, Caplan J, Brem H.

Cancer Chemother Pharmacol. 2007 Oct;60(5):643-50. Epub 2007 Jan 26.

PMID:
17256133
16.

NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.

Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.

Cancer Lett. 2015 Oct 10;367(1):58-68. doi: 10.1016/j.canlet.2015.07.007. Epub 2015 Jul 15.

PMID:
26188279
17.

Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin.

Li XQ, Ouyang ZG, Zhang SH, Liu H, Shang Y, Li Y, Zhen YS.

Cancer Biol Ther. 2014 Apr;15(4):398-408. doi: 10.4161/cbt.27626. Epub 2014 Jan 14.

18.

Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.

Recinos VR, Tyler BM, Bekelis K, Sunshine SB, Vellimana A, Li KW, Brem H.

Neurosurgery. 2010 Mar;66(3):530-7; discussion 537. doi: 10.1227/01.NEU.0000365263.14725.39.

PMID:
20173548
19.

Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.

Zhou Q, Gallo JM.

Neuro Oncol. 2009 Jun;11(3):301-10. doi: 10.1215/15228517-2008-088. Epub 2008 Oct 29.

20.

Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.

Dong J, Zhou G, Tang D, Chen Y, Cui B, Dai X, Zhang J, Lan Q, Huang Q.

J Cancer Res Clin Oncol. 2012 Dec;138(12):2079-84. doi: 10.1007/s00432-012-1290-3. Epub 2012 Jul 24.

PMID:
22825126
Items per page

Supplemental Content

Write to the Help Desk